Actively Recruiting
Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration
Led by Hospital Authority, Hong Kong · Updated on 2025-10-01
40
Participants Needed
1
Research Sites
75 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
We aimed to investigate the success rate of a planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab, for nAMD to achieve stability without recurrence at a tertiary eye centre.
CONDITIONS
Official Title
Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 50 years
- Diagnosis of neovascular AMD with involvement of the central retina (foveal involvement)
- Includes both treatment-naive and recurrent cases
- Active subfoveal macular neovascularization, including types 1, 2, and 3
You will not qualify if you...
- Received any anti-VEGF therapy in the prior six months
- Presence of other eye diseases such as diabetic macular edema, retinal vein occlusions, central serous chorioretinopathy, or myopic macular neovascularization
- Underwent macular laser treatment (except photodynamic therapy) or ocular surgery (e.g., cataract surgery or vitrectomy) within the prior six months and during the study period
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Ophthalmology, United Chrisitian Hospital
Hong Kong, Hong Kong
Actively Recruiting
Research Team
D
Daniel Ho Tak Wong, FRCOphth (UK)
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here